|
End-of-day quote
Korea S.E.
2026-09-23
|
5-day change | 1st Jan Change | ||
| 8,150.00 KRW | -0.61% |
|
-2.04% | -27.62% |
| 09-20 | Englewood Lab, Inc.(KOSDAQ:A950140) dropped from S&P Global BMI Index | CI |
| 08-11 | Englewood Lab, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| Fiscal Period: December | 2016 (KRW) | 2017 (KRW) | 2018 (KRW) | 2019 (KRW) | 2020 (KRW) | 2021 (KRW) | 2022 (KRW) | 2023 (KRW) | 2024 (KRW) | 2025 (KRW) |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 8.92 | 4.69 | 11.67 | 6.29 | 10.94 | |||||
Return on Total Capital | 10.95 | 5.43 | 14.65 | 7.78 | 12.8 | |||||
Return On Equity % | 21.18 | 8.35 | 19.95 | 15.17 | 16.09 | |||||
Return on Common Equity | 21.18 | 8.35 | 19.95 | 15.17 | 16.09 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 21.27 | 16.97 | 23.05 | 21.1 | 27.63 | |||||
SG&A Margin | 8.22 | 8.18 | 7.81 | 8.48 | 8.53 | |||||
EBITDA Margin % | 13.19 | 9.39 | 16.08 | 13.12 | 19.65 | |||||
EBITA Margin % | 10.58 | 6.63 | 14.03 | 10.46 | 17.52 | |||||
EBIT Margin % | 10.51 | 6.52 | 13.95 | 10.31 | 17.24 | |||||
Income From Continuing Operations Margin % | 9.33 | 4.8 | 10.03 | 10.77 | 11.45 | |||||
Net Income Margin % | 9.33 | 4.8 | 10.03 | 10.77 | 11.45 | |||||
Net Avail. For Common Margin % | 9.33 | 4.8 | 10.03 | 10.77 | 11.45 | |||||
Normalized Net Income Margin | 6.67 | 3.81 | 8.58 | 8.83 | 10.3 | |||||
Levered Free Cash Flow Margin | -10.44 | 0.15 | 7.54 | -2.6 | 4.64 | |||||
Unlevered Free Cash Flow Margin | -10.16 | 0.56 | 7.75 | -2.29 | 4.97 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.36 | 1.15 | 1.34 | 0.98 | 1.02 | |||||
Fixed Assets Turnover | 4.22 | 3.99 | 5.5 | 4.5 | 4.88 | |||||
Receivables Turnover (Average Receivables) | 5.63 | 4.29 | 4.02 | 2.82 | 3 | |||||
Inventory Turnover (Average Inventory) | 3.48 | 3.01 | 3.69 | 3.5 | 3.93 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.14 | 2.7 | 2.56 | 3.33 | 3.55 | |||||
Quick Ratio | 1.59 | 1.35 | 1.71 | 2.31 | 2.68 | |||||
Operating Cash Flow to Current Liabilities | -0.25 | 0.27 | 0.4 | 0.32 | 0.45 | |||||
Days Sales Outstanding (Average Receivables) | 64.82 | 85.02 | 90.73 | 129.98 | 121.77 | |||||
Days Outstanding Inventory (Average Inventory) | 104.84 | 121.45 | 98.93 | 104.52 | 92.88 | |||||
Average Days Payable Outstanding | 33 | 23.79 | 38.98 | 41.01 | 19.05 | |||||
Cash Conversion Cycle (Average Days) | 136.66 | 182.68 | 150.68 | 193.49 | 195.6 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 34.89 | 27.04 | 11.33 | 21.07 | 15.8 | |||||
Total Debt / Total Capital | 25.86 | 21.28 | 10.18 | 17.4 | 13.64 | |||||
LT Debt/Equity | 21.44 | 7.01 | 3.65 | 5.3 | 3.68 | |||||
Long-Term Debt / Total Capital | 15.89 | 5.52 | 3.28 | 4.37 | 3.18 | |||||
Total Liabilities / Total Assets | 36.85 | 31.28 | 33.82 | 27.96 | 27.51 | |||||
EBIT / Interest Expense | 22.81 | 10.11 | 41.28 | 20.73 | 32.31 | |||||
EBITDA / Interest Expense | 28.62 | 14.56 | 47.57 | 26.37 | 36.83 | |||||
(EBITDA - Capex) / Interest Expense | 25.42 | 10.37 | 43.88 | 20.44 | 31.03 | |||||
Total Debt / EBITDA | 1.33 | 1.77 | 0.39 | 1.27 | 0.61 | |||||
Net Debt / EBITDA | 0.9 | 0.99 | -0.15 | -0.35 | -0.54 | |||||
Total Debt / (EBITDA - Capex) | 1.5 | 2.48 | 0.42 | 1.64 | 0.72 | |||||
Net Debt / (EBITDA - Capex) | 1.01 | 1.38 | -0.16 | -0.46 | -0.64 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 17.24 | -5.79 | 36.48 | -11.88 | 18.97 | |||||
Gross Profit, 1 Yr. Growth % | 37.84 | -24.84 | 85.39 | -19.34 | 55.82 | |||||
EBITDA, 1 Yr. Growth % | 72.33 | -32.91 | 133.65 | -28.08 | 78.16 | |||||
EBITA, 1 Yr. Growth % | 114.7 | -40.99 | 188.88 | -34.28 | 99.31 | |||||
EBIT, 1 Yr. Growth % | 114.82 | -41.55 | 192.01 | -34.86 | 98.82 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 386.63 | -51.56 | 185.5 | -5.37 | 26.42 | |||||
Net Income, 1 Yr. Growth % | 386.63 | -51.56 | 185.5 | -5.37 | 26.42 | |||||
Normalized Net Income, 1 Yr. Growth % | 180.58 | -46.25 | 207.75 | -9.38 | 38.77 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 386.63 | -51.56 | 185.5 | -5.37 | 26.42 | |||||
Accounts Receivable, 1 Yr. Growth % | 61.36 | 0.16 | 91.04 | -8.19 | 33.49 | |||||
Inventory, 1 Yr. Growth % | 18.52 | 12.21 | -5.13 | -4.45 | -1.01 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -3.6 | 2.69 | -4.55 | 20.75 | 0.32 | |||||
Total Assets, 1 Yr. Growth % | 17.9 | 5.61 | 28.26 | 15.03 | 13.67 | |||||
Tangible Book Value, 1 Yr. Growth % | 33.04 | 15.04 | 23.82 | 24.42 | 14.92 | |||||
Common Equity, 1 Yr. Growth % | 33.44 | 14.92 | 23.53 | 25.22 | 14.38 | |||||
Cash From Operations, 1 Yr. Growth % | -194.05 | -239.29 | 115.86 | -32.55 | 60.86 | |||||
Capital Expenditures, 1 Yr. Growth % | -40.47 | 73.12 | -37.05 | 108.19 | 24.91 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -408.98 | -101.36 | 6.58K | -130.41 | -311.91 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -370.14 | -105.07 | 1.8K | -126.05 | -357.99 | |||||
Dividend Per Share, 1 Yr. Growth % | - | - | - | - | 101 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 9.83 | 5.1 | 13.39 | 9.67 | 2.39 | |||||
Gross Profit, 2 Yr. CAGR % | 16.04 | 1.78 | 18.04 | 22.29 | 12.11 | |||||
EBITDA, 2 Yr. CAGR % | 37.09 | 7.53 | 25.21 | 29.63 | 13.19 | |||||
EBITA, 2 Yr. CAGR % | 58.24 | 12.56 | 30.56 | 37.78 | 14.45 | |||||
EBIT, 2 Yr. CAGR % | 58.3 | 12.06 | 30.65 | 37.91 | 13.8 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 157.12 | 53.54 | 17.6 | 64.36 | 9.38 | |||||
Net Income, 2 Yr. CAGR % | 157.12 | 53.54 | 17.6 | 64.36 | 9.38 | |||||
Normalized Net Income, 2 Yr. CAGR % | 74.16 | 22.81 | 28.61 | 67 | 12.14 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 157.12 | 53.54 | 17.6 | 64.36 | 9.38 | |||||
Accounts Receivable, 2 Yr. CAGR % | 20.42 | 27.13 | 38.33 | 32.44 | 10.71 | |||||
Inventory, 2 Yr. CAGR % | 15.44 | 15.32 | 3.17 | -4.79 | -2.75 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -7.24 | -0.5 | -1 | 7.36 | 10.06 | |||||
Total Assets, 2 Yr. CAGR % | 5.42 | 11.59 | 16.39 | 21.46 | 14.35 | |||||
Tangible Book Value, 2 Yr. CAGR % | 14.96 | 23.71 | 19.35 | 24.12 | 19.57 | |||||
Common Equity, 2 Yr. CAGR % | 15.08 | 23.83 | 19.15 | 24.37 | 19.68 | |||||
Cash From Operations, 2 Yr. CAGR % | -24.73 | 14.46 | 73.4 | 20.66 | 4.16 | |||||
Capital Expenditures, 2 Yr. CAGR % | -30.46 | 1.52 | 4.39 | 14.48 | 61.26 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 39.85 | -79.27 | -4.57 | 350.65 | -19.72 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 33.21 | -62.63 | -1.9 | 122.37 | -18.02 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 10.63 | 4.36 | 14.66 | 4.25 | 12.69 | |||||
Gross Profit, 3 Yr. CAGR % | 21.65 | 0.4 | 24.3 | 3.97 | 32.58 | |||||
EBITDA, 3 Yr. CAGR % | 97.02 | 8.03 | 39.27 | 4.08 | 44.12 | |||||
EBITA, 3 Yr. CAGR % | 311.18 | 13.9 | 54.11 | 3.86 | 55.83 | |||||
EBIT, 3 Yr. CAGR % | 292.85 | 13.57 | 54.2 | 3.6 | 55.8 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 36.48 | 47.4 | 88.81 | 9.38 | 50.6 | |||||
Net Income, 3 Yr. CAGR % | 36.48 | 47.4 | 88.81 | 9.38 | 50.6 | |||||
Normalized Net Income, 3 Yr. CAGR % | 138.83 | 17.7 | 66.81 | 14.45 | 57 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 36.48 | 47.4 | 88.81 | 9.38 | 50.6 | |||||
Accounts Receivable, 3 Yr. CAGR % | 16.97 | 13.24 | 45.61 | 20.66 | 32.79 | |||||
Inventory, 3 Yr. CAGR % | 7.21 | 14.35 | 8.06 | 0.57 | -3.55 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -6 | -4.04 | -1.87 | 5.78 | 4.96 | |||||
Total Assets, 3 Yr. CAGR % | 6.95 | 5.48 | 16.89 | 15.93 | 18.81 | |||||
Tangible Book Value, 3 Yr. CAGR % | 12.49 | 14.99 | 23.75 | 21.02 | 20.97 | |||||
Common Equity, 3 Yr. CAGR % | 12.6 | 15.03 | 23.73 | 21.14 | 20.95 | |||||
Cash From Operations, 3 Yr. CAGR % | -9.85 | -7.59 | 41.41 | 26.58 | 32.8 | |||||
Capital Expenditures, 3 Yr. CAGR % | -43.61 | -5.76 | -13.43 | 31.4 | 17.85 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -10.05 | -69.93 | 42.08 | -34.82 | 250.44 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -10.26 | -54.9 | 38.4 | -36.95 | 133.66 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 15.22 | 11.7 | 11.73 | 6.45 | 9.59 | |||||
Gross Profit, 5 Yr. CAGR % | 11.55 | 16.18 | 20.19 | 8.64 | 19.27 | |||||
EBITDA, 5 Yr. CAGR % | 22.11 | 14.7 | 64.34 | 16.2 | 28.19 | |||||
EBITA, 5 Yr. CAGR % | 19.35 | 2.51 | 159.86 | 22.91 | 36.81 | |||||
EBIT, 5 Yr. CAGR % | 19.2 | 2.18 | 152.92 | 22.74 | 36.56 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 121.12 | -12.14 | 28.59 | 53.97 | 51.77 | |||||
Net Income, 5 Yr. CAGR % | 121.12 | -12.14 | 28.59 | 53.97 | 51.77 | |||||
Normalized Net Income, 5 Yr. CAGR % | 51.45 | 0.95 | 86.45 | 35.38 | 42.31 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 101.01 | -12.48 | 28.59 | 53.97 | 51.77 | |||||
Accounts Receivable, 5 Yr. CAGR % | 23.15 | 18.22 | 25.09 | 20.56 | 30.49 | |||||
Inventory, 5 Yr. CAGR % | 13.65 | 16.8 | 5.58 | 6.27 | 3.6 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 34.47 | 1.81 | -4.03 | 0.37 | 2.74 | |||||
Total Assets, 5 Yr. CAGR % | 8.7 | 7.93 | 10.63 | 11.61 | 15.87 | |||||
Tangible Book Value, 5 Yr. CAGR % | 1.43 | 10.21 | 15.18 | 18.56 | 22.06 | |||||
Common Equity, 5 Yr. CAGR % | 1.59 | 9.05 | 15.17 | 18.68 | 22.09 | |||||
Cash From Operations, 5 Yr. CAGR % | 14.38 | 1.26 | 17.11 | 2.82 | 25.14 | |||||
Capital Expenditures, 5 Yr. CAGR % | -17.42 | -16.75 | -27.86 | 1.87 | 11.03 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 11.16 | -57.14 | -7.54 | -11.2 | 13.07 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 10.97 | -44.46 | -6.64 | -14.62 | 12.24 |
- Stock Market
- Stocks
- A950140 Stock
- Financials Englewood Lab, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















